We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current RGEN market cap is 9.24B. The company's latest EPS is USD 0.7455 and P/E is 222.44.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 203.05M | 203.89M | 182.66M | 159.17M | 172.46M |
| Operating Income | 52.67M | 48.84M | 31.26M | 19.4M | 1.78M |
| Net Income | 40.41M | 48.73M | 28.83M | 20.06M | 18.17M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 270.25M | 366.26M | 670.53M | 830.27M | 669.33M |
| Operating Income | 36.08M | 69.82M | 167.25M | 224.67M | 54.58M |
| Net Income | 21.41M | 59.93M | 128.29M | 185.96M | 41.58M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 2.46B | 2.52B | 2.54B | 2.55B | 2.51B |
| Total Liabilities | 627.42M | 613.96M | 597.74M | 578.08M | 525.57M |
| Total Equity | 1.84B | 1.91B | 1.94B | 1.97B | 1.99B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 1.4B | 1.9B | 2.36B | 2.52B | 2.82B |
| Total Liabilities | 340.35M | 373.74M | 608.29M | 613.96M | 853.21M |
| Total Equity | 1.06B | 1.53B | 1.75B | 1.91B | 1.97B |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 110.2M | 172.08M | 11.15M | 45.62M | 84.85M |
| Investing | -111.93M | -233.24M | -9.43M | 55.4M | 46.63M |
| Financing | -13.06M | -13.34M | -9.56M | -18.39M | -19.17M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 67.22M | 62.63M | 119.02M | 172.08M | 113.92M |
| Investing | -205.31M | -201.39M | -221.17M | -233.24M | -123.28M |
| Financing | 484.87M | 305.92M | 961k | -13.34M | 248.96M |
| Market Cap | 9.24B |
| Price to Earnings Ratio | 222.44 |
| Price to Sales Ratio | 13.82 |
| Price to Cash Ratio | 12.31 |
| Price to Book Ratio | 4.69 |
| Dividend Yield | - |
| Shares Outstanding | 55.77M |
| Average Volume (1 week) | 586.72k |
| Average Volume (1 Month) | 492.52k |
| 52 Week Change | 1.03% |
| 52 Week High | 211.13 |
| 52 Week Low | 110.45 |
| Spread (Intraday) | 9.75 (5.54%) |
| Company Name | Repligen Corp |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.repligen.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
